Dermata Therapeutics Warrant
DRMAW
DRMAW was delisted on the 17th of August, 2026.
6 hedge funds and large institutions have $506K invested in Dermata Therapeutics Warrant in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$334K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$103K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$77K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$41.2K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$12.3K |
Top Sellers
DRMAW Hedge Fund Activity: Q3 2021 in Review
6 of the 5,588 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics Warrant (DRMAW) for Q3 2021, worth a combined $506K.
Buyers outnumbered sellers: 6 funds opened new DRMAW positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $334K.
- 6 institutional investors held Dermata Therapeutics Warrant (DRMAW) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $506K of Dermata Therapeutics Warrant stock for Q3 2021.
- 6 funds opened new Dermata Therapeutics Warrant positions in Q3 2021 and 0 closed out, a net change of +6 holders.
- The largest Dermata Therapeutics Warrant buyer in Q3 2021 was Armistice Capital, an estimated $334K added.
Based on aggregated 13F filings for Q3 2021.